Wire · opportunities
Adults Newly Facing Leukemia Treatment Gain Another Pill Option as FDA Clears Jaypirca ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 October 2026 · Fusion42 review
The U.S. FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion, based on data showing significant delay in disease progression compared to chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 2 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
You now have an additional oral therapy approved for first-line CLL treatment, shifting patient choice and treatment sequencing. This widens options for oncology founders focused on blood cancers to explore combination or monitoring support products.
◆ Coverage
9 sources · first reported 2 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics